SYRE - Company ID 0001636282
The table below shows Spyre Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $886.00K | $2.33M | $18.74M | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | $58.58M | $57.07M | $59.64M |
| SG&A |
Spyre Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2025. Over the 10 fiscal years shown, annual revenue declined from $4.63M (FY 2016) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $47.91M |
| $45.78M |
| $39.95M |
| $28.53M |
| $27.32M |
| $21.84M |
| Operating income | -$209.56M | -$208.57M | -$242.30M | -$84.78M | -$65.65M | -$81.48M |
| Income tax | -$15.00K | $51.00K | -$26.00K | -$136.00K | $141.00K | $0.00 |
| Net income | -$155.20M | -$208.02M | -$338.79M | -$83.81M | -$65.80M | -$80.89M |
| EPS (diluted) | - | - | $13.76 | -$24.86 | -$25.02 | -$1.52 |